Aytu BioScience, Inc

(NASDAQ:AYTU)

Latest On Aytu BioScience, Inc (AYTU):

Date/Time Type Description Signal Details
2023-05-19 21:44 ESTNewsAytu BioPharma, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-12 06:43 ESTNewsAytu BioPharma, Inc. (AYTU) Q3 2023 Earnings Call TranscriptN/A
2023-05-11 17:07 ESTNewsAytu BioScience GAAP EPS of -$1.93 misses by $1.30, revenue of $22.7M misses by $5.3MN/A
2023-05-11 02:25 ESTNewsAytu BioScience FQ3 2023 Earnings PreviewN/A
2023-02-21 21:56 ESTNewsAytu BioScience GAAP EPS of -$2.15, revenue of $26.28MN/A
2023-02-21 21:56 ESTNewsAytu BioPharma, Inc. (AYTU) Q2 2023 Earnings Call TranscriptN/A
2023-02-14 06:25 ESTNewsAytu BioScience FQ2 2023 Earnings PreviewN/A
2023-01-25 14:12 ESTNewsAytu Biopharma regains compliance with NasdaqN/A
2023-01-06 09:29 ESTNewsAytu BioPharma down 95% on 1-for-10 reverse stock split to regain Nasdaq complianceN/A
2022-11-23 10:02 ESTNewsNasdaq gives Aytu BioPharma 180-day extension to comply with bid price ruleN/A
2022-11-14 23:02 ESTNewsAytu BioScience GAAP EPS of -$0.06, revenue of $27.66MN/A
2022-11-14 23:02 ESTNewsAytu BioPharma, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-14 23:01 ESTNewsAytu BioPharma, Inc. (AYTU) Q1 2023 Earnings Call TranscriptN/A
2022-11-13 12:13 ESTNewsAytu BioScience Q1 Earnings PreviewN/A
2022-10-14 00:02 ESTNewsAytu stock falls amid suspending clinical programs to save costsN/A
2022-09-29 07:09 ESTNewsAytu BioPharma, Inc. (AYTU) Q4 2022 Results - Earnings Call TranscriptN/A
2022-09-28 00:20 ESTNewsAytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95MN/A
2022-09-28 00:20 ESTNewsAytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call TranscriptN/A
2022-09-14 19:02 ESTNewsAytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorderN/A
2022-08-16 21:50 ESTNewsAytu gets US patent for AR101/Enzastaurin for circulatory system disordersN/A
2022-08-09 19:17 ESTNewsAytu BioPharma plunges on pricing $10M stock and warrants offeringN/A
2022-08-08 20:39 ESTNewsAytu BioPharma stock slides on securities offeringN/A
2022-05-17 03:49 ESTNewsAytu BioScience GAAP EPS of -$1.79, revenue of $24.2MN/A
2022-04-25 18:06 ESTNewsAytu's Healight delivery tech delays development of ventilator-linked pneumonia in preclinical studyN/A
2022-04-19 19:27 ESTNewsAytu BioPharma stock soars 25% on FDA fast track status to AR101 for rare diseaseN/A
2022-03-03 08:15 ESTNewsAytu Biopharma prices $7.6M in stock and pre-funded warrant offeringN/A
2022-03-02 13:56 ESTNewsAytu Biopharma's AR101 for tissue disorder gets orphan status in EuropeN/A
2022-02-15 01:00 ESTNewsAytu BioScience GAAP EPS of -$0.44 beats by $0.14, revenue of $23.13M misses by $4.07MN/A
2021-12-13 15:56 ESTNewsFDA greenlights clinical trial for Aytu's VEDS drug candidateN/A
2021-11-23 17:53 ESTNewsAytu BioPharma announces patent win for experimental respiratory device, HealightN/A
2021-11-16 16:42 ESTNewsAytu Biopharma, Inc. (AYTU) CEO Josh Disbrow on Q1 2022 Results - Earnings Call TranscriptN/A
2021-11-15 21:17 ESTNewsAytu BioScience EPS misses by $0.60, misses on revenueN/A
2021-11-15 02:03 ESTNewsAytu BioScience Q1 2022 Earnings PreviewN/A
2021-11-03 08:33 ESTNewsWarning: AYTU is at high risk of performing badlyN/A
2021-09-29 10:49 ESTNewsAytu Biopharma files for $100M mixed shelf offeringN/A
2021-09-28 12:25 ESTNewsAytu BioScience EPS misses by $0.40, misses on revenueN/A
2021-09-28 12:25 ESTNewsAytu Biopharma, Inc.'s (AYTU) CEO Josh Disbrow on Q4 2021 Results - Earnings Call TranscriptN/A
2021-07-20 20:40 ESTNewsAytu BioPharma up 21% in afternoon tradingN/A
2021-07-20 20:34 ESTNewsAytu Bio's endotracheal UVA light catheter therapy significantly reduces SARS-CoV-2 viral loadN/A
2021-04-12 16:35 ESTNewsAytu Biopharma adds rare disease asset AR101 from Rumpus TherapeuticsN/A
2021-04-05 23:32 ESTNewsNew finance chief at Aytu BioPharmaN/A
2021-04-02 07:22 ESTNewsAytu BioPharma sells U.S. rights to Natesto to AcerusN/A
2021-03-30 21:41 ESTNewsAscendis downgraded at Oppenheimer, Aytu initiated at overweight at Cantor and more in today's analyst actionN/A
2021-03-22 23:11 ESTNewsAytu Bioscience closes merger with Neos TherapeuticsN/A
2021-03-18 14:41 ESTNewsHEXO, CSIQ, LAZR and SIG among premarket gainersN/A
2021-03-16 20:07 ESTNewsAytu BioScience: The Moonshot Continues To Orbit Awaiting The Next Giant StepsN/A
2021-03-08 18:07 ESTNewsAytu stock jumps on UVA light catheter COVID-19 trial dataN/A
2021-02-18 03:12 ESTAnalyst RatingThe Analyst Target Price has decreased from $23.6 to $20.6.Neutral
2021-02-12 15:05 ESTNewsAytu BioScience, Inc. (AYTU) CEO Joshua Disbrow on Q2 2021 Results - Earnings Call TranscriptN/A
2021-02-12 07:12 ESTFinancialsCompany financials have been released.Neutral

About Aytu BioScience, Inc (AYTU):

Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. Aytu BioScience, Inc. is based in Englewood, Colorado.

AYTU Quotes by TradingView

See Advanced Chart

General

  • Name Aytu BioScience, Inc
  • Symbol AYTU
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 75
  • Last Split Factor1:10
  • Last Split Date2020-12-09
  • Fiscal Year EndJune
  • IPO Date2017-02-01
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://aytubio.com
View More

Valuation

  • Forward PE 10.7
  • Price/Sales (Trailing 12 Mt.) 1.49
  • Price/Book (Most Recent Quarter) 1.22
  • Enterprise Value Revenue 1.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.05
  • Next Year EPS Estimate -$0.83
  • Next Quarter EPS Estimate -$0.57
  • Profit Margin -43%
  • Operating Margin -38%
  • Return on Assets -10%
  • Return on Equity -34%
  • Revenue 51.68 million
  • Earnings Per Share -$3.48
  • Revenue Per Share $5.14
  • Gross Profit 20.08 million
  • Quarterly Earnings Growth 377%
View More

Highlights

  • Market Capitalization 176.68 million
  • EBITDA -14119570
  • Analyst Target Price $20.6
  • Book Value Per Share $6.30
View More

Share Statistics

  • Shares Outstanding 17.88 million
  • Shares Float 14.74 million
  • % Held by Insiders 237%
  • % Held by Institutions 25.98%
  • Shares Short 372604
  • Shares Short Prior Month 340661
  • Short Ratio 0.62
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta -0.24
  • 52 Week High $22.2
  • 52 Week Low $5.86
  • 50 Day Moving Average 8.14
  • 200 Day Moving Average 9.07
View More

Dividends

  • Dividend Date 2020-12-09
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Aytu BioScience, Inc (AYTU) Dividend Calendar:

AYTU's last dividend payment was made to shareholders on December 9, 2020.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Aytu BioScience, Inc (AYTU) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-11$N/A-$0.45-$0.44-2.27%
2020-09-302020-10-06$N/A-$0.23-$0.3533.6%
2020-06-302020-09-24$N/A-$0.20-$0.3542.86%
2020-03-312020-05-15$8.16 million-$1.50-$0.50-200%
2019-12-312020-02-13$3.18 million-$0.10-$2.4595.92%
2019-09-302019-11-14$1.44 million-$3.20-$2.75-16.36%
2019-06-302019-09-26$1.72 million-$4.21-$3.30-27.45%
2019-03-312019-05-14$2.38 million-$5.00-$5.8013.79%
2018-12-312019-02-07$1.8 million-$7.20-$3.95-82.28%
2018-09-302018-11-07$1.43 million-$19.60-$14.50-35.17%
2018-06-302018-09-06$925125$0.31
2018-03-312018-05-14$607473-$48.00-$200.0076%
2017-12-312018-02-08$1.05 million-$178.00-$356.0050%
2017-09-302017-11-09$1.08 million-$352.00-$404.0012.87%
2017-06-302017-08-31$836000-$1,340.00-$1,720.0022.09%
2017-03-312017-05-11$894000-$1,920.00-$1,700.00-12.94%
2016-12-312017-02-09$794000-$2,440.00-$1,733.33-40.77%
2016-09-302016-11-07$698000-$4,680.00-$2,573.33-81.87%
2016-06-302016-09-01$937000-$9,092.00-$3,120.00-191.41%
2016-03-312016-05-04$668000-$1,854.38
2015-12-312015-12-31$470000-$11,217.23
2015-09-302015-09-30$487000-$7,661.95
2015-03-312015-03-31$23000-$24,108.10
2014-12-312015-02-28$29000-$988.87
2014-09-302014-11-30$27000-$1,599.89
2014-06-302014-08-31$59000-$1,140.71
2014-03-312014-05-31$N/A-$1,350.18
2013-12-312014-02-28$N/A-$2,637.63
2013-09-302013-11-30$N/A-$1,961.85
2013-06-302013-08-31$750-$1,260.46
2013-03-312013-05-31-$1,585.35
2012-12-312013-02-28-$1,632.44
2012-09-302012-11-30-$2,385.94
2012-06-302012-08-31-$2,184.62
2012-03-312012-05-31-$1,442.35
2011-12-312012-02-29-$1,229.77
2011-09-302011-11-30$N/A-$2,413.06
2011-06-302011-08-31-$10,247.12
2011-03-312011-05-31-$2,871.48
2010-12-312011-02-28-$3,825.84
2010-09-302010-11-30-$2,966.23
2010-06-302010-08-31-$2,356.07
2010-03-312010-05-31-$2,495.40
2009-12-312010-02-28-$2,058.53
2009-09-302009-11-30-$3,211.20
2009-06-302009-08-31-$1,926.12
2009-03-312009-05-31-$1,633.78
2008-12-312009-02-28-$2,738.65
2008-09-302008-11-30-$3,833.03

Aytu BioScience, Inc (AYTU) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Jan 31 2020
Research Development 286572 N/A N/A 78502 78502
Income Before Tax -9.53 million N/A N/A -5.33 million -5.33 million
Selling General Administrative 12.85 million N/A N/A 9.5 million 9.5 million
Gross Profit -6 million N/A N/A 6.16 million 6.16 million
Ebit -9.15 million N/A N/A -3.17 million -3.17 million
Operating Income -5.58 million N/A N/A -4.79 million -4.79 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A 8.16 million 8.16 million
Cost of Revenue 6 million N/A N/A 2 million 2 million
Total Other Income Expense Net N/A N/A N/A -538862 -538862
Net Income From Continuing Operations -9.53 million N/A N/A -5.33 million -5.33 million
Net Income Applicable to Common Shares -9.53 million -4.31 million -3.15 million N/A N/A
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Jan 31 2020 Dec 31 2019
Investments N/A N/A 343903 343903 N/A
Change to Liabilities -4.63 million 3.42 million N/A N/A 2.53 million
Total Cash Flow from Investing Activities -16940 -45040 N/A N/A -4.91 million
Net Borrowings -136364 -16.89 million N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A 68.18 million 68.18 million 9.26 million
Change to Operating Activities 1.05 million -5.02 million N/A N/A -982470
Change in Cash N/A N/A 57.01 million 57.01 million -1.75 million
Total Cash from Operating Activities -7.97 million -7.76 million -11.52 million -11.52 million -6.1 million
Depreciation N/A N/A 1.62 million 1.62 million 1.29 million
Other Cash Flow from Investing Activities 2200 6000 N/A N/A -350000
Change to Inventory N/A N/A -213253 -213253 -191539
Change to Account Receivables N/A N/A -4.73 million -4.73 million -3.49 million
Other Cash Flow from Financing Activities -2.04 million -123725 N/A N/A -741650
Change to Net Income 221915 -3.51 million N/A N/A -5.04 million
Capital Expenditures N/A N/A N/A N/A 4.5 million
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 54.05 million N/A N/A 73.25 million 57.39 million
Total Stockholder Equity 112.69 million N/A N/A 85.7 million 17.09 million
Other Current Liabilities 5.26 million 6.38 million 4.23 million 19.13 million 3.37 million
Total Assets 166.74 million N/A N/A 158.95 million 74.48 million
Common Stock 1788 12584 12584 N/A 2073
Other Current Assets 16.93 million 6.27 million 5.99 million 1.85 million 1.68 million
Retained Earnings -133.84 million -124.32 million -120.01 million -116.87 million -111.53 million
Other Liabilities N/A 28.46 million 28.79 million N/A 41.15 million
Other Assets N/A 9900 32981 N/A 2200
Cash 62.03 million N/A N/A 62.26 million 5.26 million
Total Current Liabilities 25.81 million 21.51 million 28.31 million 42.03 million 15.95 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 89663 440442 892609 N/A 496632
Total Current Assets 92.54 million 65.45 million 74.97 million 83.25 million 18.34 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 38.9 million 15.7 million 18.07 million N/A -38.55 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt 9.95 million N/A N/A N/A N/A
Inventory 6.57 million 11.48 million 10 million 3.85 million 2.49 million
Accounts Payable 18.58 million 5.77 million 11.82 million 6.96 million 9.6 million

Aytu BioScience, Inc (AYTU) Chart:

Aytu BioScience, Inc (AYTU) News:

Below you will find a list of latest news for Aytu BioScience, Inc (AYTU) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Aytu BioScience, Inc (AYTU) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest AYTU Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST20$0.4782
Jun 13, 2022 7:59 PM EST80$0.4782
Jun 13, 2022 7:59 PM EST40$0.4782
Jun 13, 2022 7:59 PM EST49$0.4782
Jun 13, 2022 7:59 PM EST100$0.4782

Aytu BioScience, Inc (AYTU) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000121390020016604/0001213900-20-016604-index.htm
2020-02-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1385818/000000000020001798/0000000000-20-001798-index.htm
2020-06-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1385818/000000000020005255/0000000000-20-005255-index.htm
2020-06-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1385818/000000000020005256/0000000000-20-005256-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-03-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1385818/000091957420002440/0000919574-20-002440-index.htm
2020-04-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1385818/000091957420002814/0000919574-20-002814-index.htm
2020-04-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1385818/000091957420002815/0000919574-20-002815-index.htm
2020-04-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1385818/000091957420003056/0000919574-20-003056-index.htm
2020-04-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1385818/000091957420003060/0000919574-20-003060-index.htm
2020-04-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1385818/000110465920051622/0001104659-20-051622-index.htm
2020-02-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1385818/000121390020004915/0001213900-20-004915-index.htm
2020-02-28424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1385818/000121390020005050/0001213900-20-005050-index.htm
2020-03-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1385818/000121390020005175/0001213900-20-005175-index.htm
2020-03-04DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1385818/000121390020005421/0001213900-20-005421-index.htm
2020-03-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1385818/000121390020006183/0001213900-20-006183-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000121390020006187/0001213900-20-006187-index.htm
2020-03-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1385818/000121390020006269/0001213900-20-006269-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000121390020006311/0001213900-20-006311-index.htm
2020-03-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1385818/000121390020007010/0001213900-20-007010-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000121390020007021/0001213900-20-007021-index.htm
2020-03-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1385818/000121390020007140/0001213900-20-007140-index.htm
2020-03-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1385818/000121390020007828/0001213900-20-007828-index.htm
2020-04-03424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1385818/000121390020008577/0001213900-20-008577-index.htm
2020-04-09DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1385818/000121390020008861/0001213900-20-008861-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000121390020013839/0001213900-20-013839-index.htm
2020-06-08S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1385818/000121390020014381/0001213900-20-014381-index.htm
2020-06-08S-4Registration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1385818/000121390020014383/0001213900-20-014383-index.htm
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000121390020014833/0001213900-20-014833-index.htm
2020-06-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1385818/000121390020014842/0001213900-20-014842-index.htm
2020-06-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1385818/000121390020014847/0001213900-20-014847-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000121390020016604/0001213900-20-016604-index.htm
2020-09-28NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405https://www.sec.gov/Archives/edgar/data/1385818/000121390020028696/0001213900-20-028696-index.htm
2020-03-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1385818/000153561020000080/0001535610-20-000080-index.htm
2020-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1385818/000157856320000020/0001578563-20-000020-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420002568/0001654954-20-002568-index.htm
2020-03-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420002843/0001654954-20-002843-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420002956/0001654954-20-002956-index.htm
2020-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420003132/0001654954-20-003132-index.htm
2020-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420003646/0001654954-20-003646-index.htm
2020-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420003771/0001654954-20-003771-index.htm
2020-04-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420003829/0001654954-20-003829-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420004096/0001654954-20-004096-index.htm
2020-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420004130/0001654954-20-004130-index.htm
2020-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420004187/0001654954-20-004187-index.htm
2020-04-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420004215/0001654954-20-004215-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420004311/0001654954-20-004311-index.htm
2020-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420004374/0001654954-20-004374-index.htm
2020-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420004762/0001654954-20-004762-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420005000/0001654954-20-005000-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420005474/0001654954-20-005474-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1385818/000165495420005522/0001654954-20-005522-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1385818/000165495420006576/0001654954-20-006576-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1385818/000165495420006581/0001654954-20-006581-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1385818/000165495420006582/0001654954-20-006582-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1385818/000165495420006583/0001654954-20-006583-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1385818/000165495420006584/0001654954-20-006584-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1385818/000165495420006585/0001654954-20-006585-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420007046/0001654954-20-007046-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1385818/000165495420009234/0001654954-20-009234-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1385818/000165495420010889/0001654954-20-010889-index.htm
2020-10-0610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/0001654954-20-010891-index.htm
2020-02-28EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1385818/999999999520000446/9999999995-20-000446-index.htm
2020-06-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1385818/999999999520001463/9999999995-20-001463-index.htm
2020-06-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1385818/999999999520001464/9999999995-20-001464-index.htm

Aytu BioScience, Inc (AYTU) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aytu BioScience, Inc (AYTU). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 237%
Institutional Ownership: 2598%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-04-27ARMISTICE CAPITAL, LLCDirectorSell0.000.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420003060/0000919574-20-003060-index.htm
2020-04-27ARMISTICE CAPITAL, LLCDirectorSell5,108,921.001.829,298,236.220.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420003060/0000919574-20-003060-index.htm
2020-03-10ARMISTICE CAPITAL, LLCDirectorSell0.001.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-03-10ARMISTICE CAPITAL, LLCDirectorSell2,456,822.000.992,432,253.781.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-03-10ARMISTICE CAPITAL, LLCDirectorBuy1,918,587.0010,203,867.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-03-10ARMISTICE CAPITAL, LLCDirectorBuy0.0015,203,867.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-03-10ARMISTICE CAPITAL, LLCDirectorBuy5,000,000.001.005,000,000.0015,203,867.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-06-08Gary CantrellDirectorBuy10,000.00162,840.00https://www.sec.gov/Archives/edgar/data/1385818/000165495420006582/0001654954-20-006582-index.htm
2020-03-10ARMISTICE CAPITAL, LLCDirectorBuy0.0019,609,276.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-03-10ARMISTICE CAPITAL, LLCDirectorBuy4,403,409.001.004,403,409.0019,609,276.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-03-10ARMISTICE CAPITAL, LLCDirectorBuy3,907,165.001.505,860,747.5022,026,802.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-03-10ARMISTICE CAPITAL, LLCDirectorBuy0.0022,036,802.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-03-10ARMISTICE CAPITAL, LLCDirectorSell0.002,456,823.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-03-10ARMISTICE CAPITAL, LLCDirectorSell19,569,979.001.4728,767,869.132,456,823.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm
2020-04-27ARMISTICE CAPITAL, LLCDirectorBuy0.005,108,921.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420003060/0000919574-20-003060-index.htm
2020-04-27ARMISTICE CAPITAL, LLCDirectorBuy5,000,000.001.256,250,000.005,108,921.00https://www.sec.gov/Archives/edgar/data/1385818/000091957420003060/0000919574-20-003060-index.htm
2020-06-08David A GreenChief Financial OfficerBuy250,000.00521,250.00https://www.sec.gov/Archives/edgar/data/1385818/000165495420006585/0001654954-20-006585-index.htm
2020-04-15Cerecor Inc.10% Share HolderSell92,777.001.55144,091.969,713,068.00https://www.sec.gov/Archives/edgar/data/1385818/000157856320000020/0001578563-20-000020-index.htm
2020-06-08Joshua R. DisbrowChief Executive OfficerBuy450,000.00975,048.00https://www.sec.gov/Archives/edgar/data/1385818/000165495420006583/0001654954-20-006583-index.htm